Navigation Links
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
Date:10/23/2008

-- Data Presented at 20th EORTC-NCI-AACR Symposium --

SEATTLE and GENEVA, Oct. 23 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), supporting Trp-p8 as a therapeutic cancer target.

The poster, titled, "Preclinical Validation of the TrpM8 Ion Channel as a Cancer/ Benign Prostate Hyperplasia Target," was presented at the European Organization for Research and Treatment of Cancer, National Cancer Institute and American Association for Cancer Research Symposium on molecular targets and cancer therapeutics taking place in Geneva, Switzerland, on October 23, 2008.

"These data provide us with additional evidence supporting the potential for D-3263 as an important new investigational therapy for cancer and also potentially for benign prostatic hyperplasia (BPH)," said David Urdal, Ph.D., chief scientific officer of Dendreon.

Results showed that in vitro, D-3263 selectively increases the influx of calcium into Trp-p8 expressing cells leading to cell death. In in vivo animal models, D-3263 significantly inhibited the growth of Trp-p8 expressing tumors in both CHO/TRP-P8 expressing tumors as well as a human prostate cancer xenograft tumor models using the LuCaP 35 prostate cancer cell line. The mean tumor volume in the LuCaP 35 model in animals treated with D-3263 was 123.7 mm3 compared to 207.6 mm3 in the control arm (p=0.004) In addition, D-3263 significantly reduced (p=0.004) the effects of androgen-induced BPH in animal models.

"We previously reported that D-3263 can selectively kill cells that over-express Trp-p8, and these data further substantiate its attractiveness as a molecule for treating cancer and potentially BPH," said Dr. Urdal. "We look forward to filing an investigational new drug application with the U.S. Food and Drug Administration later this year to evaluate the compound in a Phase 1 dose escalation study in cancer."

About Trp-p8

Trp-p8 (also known as Trp-M8) was identified through Dendreon's in-house discovery efforts. It is an ion channel that is triggered by cold temperatures and small-molecule agonists. In normal human tissues Trp-p8 is expressed predominantly in the prostate where it is over-expressed in BPH and prostate cancer, as well as a range of other cancers including breast, lung and colon. Dendreon has synthesized bioavailable small molecule agonists that activate the Trp-p8 ion channel and induce cell death.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Dendreon Reports First Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Announces Closing of Registered Direct Offering
7. Dendreon Announces $47 Million Registered Direct Offering
8. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
9. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
10. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ANGELES , Jan. 23, 2017   Instrument ... Bio-Techne ( Minneapolis, MN ) the ... is the most authoritative newsletter tracking developments in ... market. "Bio-Techne consistently achieved outstanding technical, ... Tanya Samazan, Managing Editor of IBO. "In 2016, ...
(Date:1/24/2017)... 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... underwriting agreement with Rodman & Renshaw, a unit of ... book running manager and representative of several underwriters, under which ... commitment basis a minimum of 2,105,264 shares of common ... a minimum of 1,052,632 shares of common stock of ...
(Date:1/23/2017)... NEW YORK , Jan. 23, 2017  Spherix ... development company committed to the fostering of technology and ... its active patent infringement lawsuits. Anthony ... we enter 2017, we will continue to communicate with ... Equitable IP and our due diligence on other patent ...
(Date:1/23/2017)... CALGARY , Jan. 23, 2017 /PRNewswire/ - Resverlogix ... preliminary results from the New Zealand ... impaired patients. The data showed remarkable results in reducing ... versus healthy control patients. It is believed that this ... direct connection of this type can be made between ...
Breaking Biology Technology:
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, 2016 ... financial services provider, today announced an agreement with NuData Security, ... to join forces. The partnership will enable clients to focus ... compliance with local data protection regulation. ... In order to provide a ...
Breaking Biology News(10 mins):